Stock JUBLPHARMA JUBILANT PHARMOVA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Jubilant Pharmova Limited Stock NSE India S.E.

Equities

JUBLPHARMA

INE700A01033

Pharmaceuticals

Delayed NSE India S.E.
Other stock markets
 02:11:58 2024-07-16 am EDT 		5-day change 1st Jan Change
739 INR +1.82% Intraday chart for Jubilant Pharmova Limited +1.13% +35.70%
Jun. 25 Jubilant Pharmova Arm Completes Prepayment of $75 Million Term Loan MT
Jun. 18 Jubilant Pharmova Gets 15 Observations from US FDA for Unit's Manufacturing Facility in Canada; Shares Dip 3% MT

Financials

Sales 2022 61.3B 734M Sales 2023 62.82B 752M Capitalization 44.42B 531M
Net income 2022 4.14B 49.53M Net income 2023 -610M -7.3M EV / Sales 2022 1.37 x
Net Debt 2022 22.03B 264M Net Debt 2023 26.44B 316M EV / Sales 2023 1.13 x
P/E ratio 2022
14.9 x
P/E ratio 2023
-72.8 x
Employees 5,778
Yield 2022
1.29%
Yield 2023
1.79%
Free-Float 35.19%
More Fundamentals * Assessed data

Chart Jubilant Pharmova Limited

Dynamic Chart

Latest news about Jubilant Pharmova Limited

Jubilant Pharmova Arm Completes Prepayment of $75 Million Term Loan MT
Jubilant Pharmova Gets 15 Observations from US FDA for Unit's Manufacturing Facility in Canada; Shares Dip 3% MT
Jubilant Pharmova Unit to Prepay $75 Million Term Loan MT
Jubilant Pharma Unit to Invest $50 Million for PET Radiopharmacy Network Expansion in US MT
Jubilant Pharmova Gets Three US FDA Observations for Unit's Facility in Washington; Shares Drop 3% MT
Jubilant Pharmova Narrows Loss in Fiscal Q4 MT
India's Jubilant Pharmova reports narrower fourth-quarter loss RE
Jubilant Pharmova Limited Announces Resignation of Jinang Pratap Parekh as Whole-Time Director, Effective May 31, 2024 CI
Jubilant Pharmova Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024 CI
Jubilant Pharmova Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Jubilant Pharmova Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Jubilant Pharmova Appoints CEO for Radiopharma Business MT
Jubilant Pharmova Limited Receives Rectification Application Against Certain Tax Demands Raised by the Income Tax Department for Assessment Year 2015- 16 CI
Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA MT
Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility MT
More news

Press releases Jubilant Pharmova Limited

Jubilant Pharmova : Related Party Disclosure – 31.03.2024 PU
Jubilant Pharmova : Chairmen’s Message PU
Jubilant Pharmova : FAQ’s PU
Jubilant Pharmova : Investor Presentation- March 12, 2024 PU
Jubilant Pharmova : Sustainability Report 2022-23 PU
More press releases

Quotes and Performance

1 day+1.98%
1 week+1.13%
Current month+0.06%
1 month+0.89%
3 months+10.18%
6 months+31.71%
Current year+35.70%
More quotes

Highs and lows

1 week
712.00
Extreme 712
748.00
1 month
711.20
Extreme 711.2
780.30
Current year
532.15
Extreme 532.15
780.30
1 year
318.75
Extreme 318.75
780.30
3 years
268.90
Extreme 268.9
780.30
5 years
234.35
Extreme 234.35
1 046.95
10 years
115.60
Extreme 115.6
1 046.95
More quotes

Managers and Directors - Jubilant Pharmova Limited

Managers TitleAgeSince
Priyavrat Bhartia CEO
 Chief Executive Officer 46 17-05-22
Arjun Shanker Bhartia CEO
 Chief Executive Officer 37 17-05-22
Arvind Chokhany DFI
 Director of Finance/CFO 52 21-03-31
Members of the board TitleAgeSince
Hari Shankar Bhartia CHM
 Chairman 67 81-12-31
Shyam Sunder Bhartia CHM
 Chairman 71 78-06-20
Priyavrat Bhartia CEO
 Chief Executive Officer 46 17-05-22
More insiders

Quotes

Date Price Change Volume
24-07-16 739 +1.82% 88 148
24-07-15 725.8 +0.58% 112,621
24-07-12 721.7 -0.37% 52,491
24-07-11 724.4 -0.21% 61,333
24-07-10 725.9 -0.83% 145,353

Delayed Quote NSE India S.E., July 16, 2024 at 02:11 am EDT

More quotes

Company Profile

Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company’s segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services, and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
Sector
Pharmaceuticals
Calendar
2024-07-17 - Q1 2025 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
722.2 INR
Average target price
871 INR
Spread / Average Target
+20.61%
Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+63.05% 856B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.42% 631B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.78% 359B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.52% 325B
ABBVIE INC. Stock AbbVie Inc.
+8.43% 297B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.19% 244B
ROCHE HOLDING AG Stock Roche Holding AG
+5.81% 234B
NOVARTIS AG Stock Novartis AG
+16.77% 226B
AMGEN INC. Stock Amgen Inc.
+14.63% 177B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JUBLPHARMA Stock
  4. JUBLPHARMA Stock